Related Experiment Video
Updated: Apr 23, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
Published on: July 31, 2019
Prebiotic Oligosaccharides: Comparative Evaluation Using In Vitro Cultures of Infants' Fecal Microbiomes
J Stiverson1, T Williams2, J Chen1
1Department of Animal Sciences, The Ohio State University, Columbus, Ohio, USA.
Insights
Galacto-oligosaccharide (GOS) supplementation in infant formula significantly boosted beneficial Bifidobacterium growth, including Bifidobacterium longum. This prebiotic effect also led to higher acetic acid levels and a potential reduction in E. coli, suggesting improved infant gut health.
Area of Science:
- Microbiology
- Nutritional Science
- Pediatrics
Background:
- The infant gut microbiome plays a crucial role in health and development.
- Prebiotics are non-digestible food ingredients that selectively stimulate beneficial bacteria.
- Galacto-oligosaccharides (GOS) are commonly used prebiotics in infant nutrition.
Purpose of the Study:
- To evaluate the bifidogenic effects of commonly used prebiotic products in infant fecal cultures.
- To compare the efficacy of galacto-oligosaccharide (GOS), inulin (IN), and oligofructose-inulin (OF-IN) on gut microbiota composition.
- To assess the impact of prebiotics on specific bacterial groups like Bifidobacterium and Escherichia coli.
Main Methods:
- In vitro incubation of infant fecal samples (from breast milk and formula-fed infants) with different prebiotic products.
- Quantification of bacterial populations (total bacteria, Bifidobacterium, Bacteroides, Bifidobacterium longum, Escherichia coli) using quantitative PCR (qPCR).
- Enumeration of Bifidobacterium on selective agar, identification via 16S rRNA gene sequencing, and measurement of volatile fatty acids (VFA) and pH.
Main Results:
- Galacto-oligosaccharide (GOS) products, alone or combined with inulin, significantly increased total Bifidobacterium and Bifidobacterium longum abundance.
- Oligofructose-inulin (OF-IN) also enhanced Bifidobacterium and Bifidobacterium longum levels.
- Increased acetic acid concentrations and a trend towards lower Escherichia coli levels and pH were observed with GOS supplementation.
Conclusions:
- Galacto-oligosaccharide (GOS) demonstrated a potent bifidogenic effect and inhibited Escherichia coli growth at studied concentrations.
- Supplementation of infant formula with GOS may promote a healthier gut microbiota in infants.
- These findings support the potential benefits of GOS for infant gut health.
Abstract:
The objective of this study was to systematically assess the bifidogenic effect of three commonly used prebiotic products using in vitro cultures of infant fecal samples. Fresh stool samples collected from six term infants, each exclusively fed human milk (n = 3) or infant formula (n = 3), at 28 days of age were used as inocula. The following prebiotic products were added at concentrations applicable to infant formula: Vivinal GOS 15 (containing 28.5% galacto-oligosaccharide [GOS]) at 7.2 g/liter, Beneo HP (99.5% long-chain inulin [IN]) at 0.8 g/liter, Beneo Synergy 1 (enriched oligofructose and inulin [OF-IN]) at 4 g/liter, and a combination of Vivinal GOS 15 (7.2 g/liter) and Beneo HP (0.8 g/liter) (GOS-IN). The growth of total bacteria, Bifidobacterium, Bacteroides, Bifidobacterium longum, and Escherichia coli was quantified using specific quantitative PCR (qPCR). Bifidobacterium was also enumerated on selective Beerens agar plates, with representative colonies identified by sequencing of their 16S rRNA genes. Volatile fatty acids (VFA) and pH in the cultures were also determined. Irrespective of the feeding methods, the GOS product, either alone or in combination with Beneo HP, resulted in substantially higher growth of total bifidobacteria, and much of this growth was attributed to growth of B. longum. Beneo Synergy 1 also increased the abundance of total bifidobacteria and B. longum. Corresponding to the increases in these two bacterial groups, acetic acid concentrations were higher, while there was a trend of lower E. coli levels and pH. The lower pH and higher acetic acid concentration might be directly responsible for the lower E. coli population. At the concentrations studied, the GOS product was more bifidogenic and potent in inhibiting E. coli than the other products tested. These results suggest that supplementation of infant formula with GOS may increase intestinal bifidobacteria and benefit infant health.
Related Concept Videos
Development of Human Microbiota
Development of the Oral Microbiota
Probiotics
Introduction to the Human Microbiota
Microbiota of the Stomach and Small Intestine
Microbiota of the Large Intestine

